Novo Nordisk announced that semaglutide, a GLP‑1 receptor agonist, failed to delay disease progression in two closely watched Alzheimer’s trials. The company said neither study met the primary endpoint, dashing hopes that a diabetes/obesity drug could be rapidly repurposed for neurodegeneration. The negative readouts will force biopharma programs focused on GLP‑1s in CNS indications to reassess development strategies and resource allocation.